- TOTAL REVENUE OF $222.3
MILLION FOR THE FIRST NINE MONTHS OF 2024 VS. $178.0 MILLION FOR THE SAME PERIOD IN 2023, AN
INCREASE OF 25%
- HOSPITAL DIVISION VISITS OF 122,944 FOR THE FIRST
NINE MONTHS OF 2024 VS. VISITS OF 102,798 FOR THE SAME PERIOD IN
2023, AN INCREASE OF 20%
- HOSPITAL DIVISION OPERATING INCOME OF $54.7 MILLION FOR THE FIRST NINE MONTHS OF 2024
VS. $21.1 MILLION FOR THE SAME PERIOD
IN 2023, AN INCREASE OF 159%
- NET CASH FROM OPERATING ACTIVITIES OF $23.1 MILLION FOR THE FIRST NINE MONTHS OF
2024
- COMPANY CONTINUES ITS FOCUS ON INCREASING CASH
FLOW
HOUSTON, Nov. 7, 2024
/PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the
"Company") (NASDAQ: NUTX), a physician-led, integrated healthcare
delivery system comprised of 22 state-of-the-art micro hospitals
and hospital outpatient departments (HOPDs) in ten states and
primary care-centric, risk-bearing physician networks, today
announced third quarter 2024 financial results for the three and
nine months ended September 30,
2024.
Financial Highlights for the Three Months Ended
September 30, 2024:
- Total revenue of $78.8
million as compared to total revenue of $62.7 million for the three months ended
September 30, 2023, an increase of
26%. Of this revenue growth, mature hospitals, which are hospitals
opened prior to December 31, 2021,
increased by 20.7% in 2024 compared to the same period in
2023.
- Operating income (including the negative impact of a
$2.0 million non-cash stock-based
compensation expense) for the three months ended September 30, 2024 was $9.7 million, compared to an operating loss of
approximately $0.8 million for the
three months ended September 30,
2023, representing a $10.5
million improvement quarter over quarter.
- Net loss attributable to Nutex Health of $8.8 million in the three months ended
September 30, 2024 as compared to a
net loss attributable to Nutex Health of $5.5 million for the three months ended
September 30, 2023. This $8.8 million amount includes a $6.7 million non-cash loss on warrant liability
as well as the $2.0 million non-cash
stock-based compensation expense noted above.
- EBITDA attributable to Nutex Health of $4.3 million, as compared to EBITDA attributable
to Nutex Health of $1.2 million
for the three months ended September 30,
2023.
- Adjusted EBITDA attributable to Nutex Health of
$13.5 million, as compared to
Adjusted EBITDA attributable to Nutex Health of $1.3 million for the three months ended
September 30, 2023, an increase of 938%.
- Total visits from the Hospital Division were 41,668 for
the third quarter 2024, as compared to 37,443 for the third quarter
2023, an increase of 4,225 or 11.3%. Of this visit growth, mature
hospitals increased by 3.8% in 2024 compared to the same period in
2023.
Financial Highlights for the Nine Months Ended
September 30, 2024:
- Total revenue of $222.3
million as compared to total revenue of $178.0 million for the nine months ended
September 30, 2023, an increase of
approximately 25%. Of this revenue growth, mature hospitals, which
are hospitals opened prior to December 31, 2021,
increased by 13.5% in 2024 compared to 2023.
- Operating income for the nine months ended September 30, 2024 was $16.4 million compared to an operating loss of
$5.6 million for the nine months
ended September 30, 2023,
representing a $22.0 million
improvement year over year.
- Net loss attributable to Nutex Health of $9.5 million as compared to net loss attributable
to Nutex Health of $14.2 million
for the nine months ended September 30,
2023. This $9.5 million amount
includes non-cash items of $10.2
million (non-cash stock-based compensation expense of
$2.0 million, non-cash impairment of
assets of $3.9 million, non-cash
impairment of goodwill of $3.2
million and $1.1 million
non-cash loss on warrant liability) in the first nine months of
2024, while the $14.2 million amount
includes non-cash stock-based compensation expense of $2.2 million in the first nine months of
2023.
- EBITDA attributable to Nutex Health of $19.9 million, as compared to EBITDA attributable
to Nutex Health of $5.3 million
for the nine months ended September 30,
2023.
- Adjusted EBITDA attributable to Nutex Health of
$30.1 million, as compared to
Adjusted EBITDA attributable to Nutex Health of $7.7 million for the nine months ended
September 30, 2023, an increase of
290%.
- Total visits from the Hospital Division were 122,944 for
the nine months ended September 30,
2024, as compared to 102,798 for the same period in 2023, an
increase of 20,146 or 19.6%. Of this visit growth, mature hospitals
increased by 7.7% in the nine months ended September 30, 2024 compared to the same period in
2023.
- Net cash from operating activities of $23.1 million for the nine months ended
September 30, 2024.
- As of September 30, 2024,
the Company had total assets of $438.5
million, including cash and cash equivalents of $46.9 million and long-term debt of $26.8 million.
Note: EBITDA and Adjusted EBITDA are non-GAAP financial
metrics. A reconciliation of non-GAAP to GAAP measures is included
below in this earnings release.
"We are pleased to report 25% revenue growth, Adjusted
EBITDA attributable to Nutex Health of $13.5
million and a 209% increase in gross profit to $21.9 million in the third quarter ended
September 30, 2024, showing our
continued focus on top line growth, increasing cash flow as well as
improving profitability," stated Jon
Bates, Chief Financial Officer of Nutex Health.
"Nutex Health had another outstanding quarter. The
strategic and operational decisions we have made over the last nine
months are driving this strong performance, as demonstrated by
another quarter of year-over-year growth in revenue, EBITDA and
Adjusted EBITDA as well as incremental growth in cash flow. We are
confident that our momentum will continue and plan on growing our
hospital and population health divisions responsibly as we drive
value for our shareholders," stated Warren
Hosseinion, M.D., President of Nutex Health.
"The four de-novo hospitals that we opened in 2023 are
ramping up nicely, resulting in strong year-over-year growth in
both revenue and patient volume. Volumes and revenue continue to
increase among our mature hospitals, both on the outpatient side as
well as the inpatient side, which still have excess capacity. Our
average payment by insurers of patient claims also increased, a
trend we are optimistic will persist as we continue to work
the NSA (No Surprises Act) claims through the Independent
Dispute Resolution process," stated Tom
Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex
Health.
For more details on the Company's Third Quarter 2024
financial results, please refer to our Quarterly Report on Form
10-Q filed with the U.S. Securities & Exchange Commission and
accessible at www.sec.gov.
|
NUTEX HEALTH
INC.
CONDENSED
CONSOLIDATED BALANCE SHEETS
(Unaudited)
|
|
|
|
September 30, 2024
|
|
December 31, 2023
|
|
Assets
|
|
|
|
|
|
|
|
Current
assets:
|
|
|
|
|
|
|
|
Cash and cash
equivalents
|
|
$
|
46,909,281
|
|
$
|
22,002,056
|
|
Accounts
receivable
|
|
|
62,745,336
|
|
|
58,624,301
|
|
Accounts receivable -
related parties
|
|
|
3,602,189
|
|
|
4,152,068
|
|
Inventories
|
|
|
2,259,168
|
|
|
3,390,584
|
|
Prepaid expenses and
other current assets
|
|
|
4,279,360
|
|
|
2,679,394
|
|
Total current
assets
|
|
|
119,795,334
|
|
|
90,848,403
|
|
Property and equipment,
net
|
|
|
78,246,467
|
|
|
81,387,649
|
|
Operating right-of-use
assets
|
|
|
11,442,369
|
|
|
11,853,082
|
|
Finance right-of-use
assets
|
|
|
198,462,381
|
|
|
176,146,329
|
|
Intangible assets,
net
|
|
|
15,855,392
|
|
|
20,512,636
|
|
Goodwill,
net
|
|
|
13,918,719
|
|
|
17,066,263
|
|
Other assets
|
|
|
767,942
|
|
|
431,135
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
438,488,604
|
|
$
|
398,245,497
|
|
|
|
|
|
|
|
|
Liabilities and Equity
|
|
|
|
|
|
|
|
Current
liabilities:
|
|
|
|
|
|
|
|
Accounts
payable
|
|
$
|
10,320,933
|
|
$
|
18,899,196
|
|
Accounts payable -
related parties
|
|
|
6,342,883
|
|
|
6,382,197
|
|
Lines of
credit
|
|
|
3,384,517
|
|
|
3,371,676
|
|
Current portion of
long-term debt
|
|
|
10,499,532
|
|
|
10,808,721
|
|
Operating lease
liabilities, current portion
|
|
|
2,060,758
|
|
|
1,579,987
|
|
Finance lease
liabilities, current portion
|
|
|
5,261,458
|
|
|
4,315,979
|
|
Accrued expenses and
other current liabilities
|
|
|
29,688,665
|
|
|
12,955,296
|
|
Total current
liabilities
|
|
|
67,558,746
|
|
|
58,313,052
|
|
Long-term debt,
net
|
|
|
26,801,811
|
|
|
26,314,733
|
|
Warrant
liability
|
|
|
5,715,143
|
|
|
-
|
|
Operating lease
liabilities, net
|
|
|
14,307,320
|
|
|
15,479,639
|
|
Finance lease
liabilities, net
|
|
|
240,924,194
|
|
|
213,886,213
|
|
Deferred tax
liabilities
|
|
|
3,402,965
|
|
|
5,145,754
|
|
Total
liabilities
|
|
|
358,710,179
|
|
|
319,139,391
|
|
|
|
|
|
|
|
|
Commitments and
contingencies
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Equity:
|
|
|
|
|
|
|
|
Common stock, $0.001
par value; 950,000,000 shares authorized; 5,215,709 and
4,511,199
shares issued and outstanding as of September 30, 2024
and December 31, 2023,
respectively
|
|
|
5,216
|
|
|
4,511
|
|
Additional paid-in
capital
|
|
|
479,024,452
|
|
|
470,521,218
|
|
Accumulated
deficit
|
|
|
(418,588,975)
|
|
|
(409,072,539)
|
|
Nutex Health Inc.
equity
|
|
|
60,440,693
|
|
|
61,453,190
|
|
Noncontrolling
interests
|
|
|
19,337,732
|
|
|
17,652,916
|
|
Total equity
|
|
|
79,778,425
|
|
|
79,106,106
|
|
|
|
|
|
|
|
|
Total liabilities and
equity
|
|
$
|
438,488,604
|
|
$
|
398,245,497
|
|
NUTEX HEALTH
INC.
CONDENSED
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
|
|
|
|
Three Months Ended
September 30,
|
|
Nine Months Ended
September 30,
|
|
|
2024
|
|
2023
|
|
2024
|
|
2023
|
|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Hospital
division
|
|
$
|
71,732,529
|
|
$
|
54,585,263
|
|
$
|
199,366,776
|
|
$
|
155,485,230
|
|
Population health
management division
|
|
|
7,062,340
|
|
|
8,137,709
|
|
|
22,964,141
|
|
|
22,491,613
|
|
Total
revenue
|
|
|
78,794,869
|
|
|
62,722,972
|
|
|
222,330,917
|
|
|
177,976,843
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating costs and
expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payroll and
benefits
|
|
|
29,848,083
|
|
|
28,873,144
|
|
|
85,249,302
|
|
|
79,570,519
|
|
Contract
services
|
|
|
11,657,010
|
|
|
9,035,650
|
|
|
32,481,686
|
|
|
27,972,854
|
|
Medical
supplies
|
|
|
3,982,598
|
|
|
3,460,130
|
|
|
12,892,904
|
|
|
10,748,214
|
|
Depreciation and
amortization
|
|
|
4,972,478
|
|
|
4,745,941
|
|
|
13,691,484
|
|
|
12,908,848
|
|
Other
|
|
|
6,417,886
|
|
|
9,541,894
|
|
|
23,380,318
|
|
|
25,215,549
|
|
Total operating costs
and expenses
|
|
|
56,878,055
|
|
|
55,656,759
|
|
|
167,695,694
|
|
|
156,415,984
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
profit
|
|
|
21,916,814
|
|
|
7,066,213
|
|
|
54,635,223
|
|
|
21,560,859
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Corporate and other
costs:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Facilities closing
costs
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
217,266
|
|
Acquisition
costs
|
|
|
-
|
|
|
43,464
|
|
|
-
|
|
|
43,464
|
|
Stock-based
compensation expense
|
|
|
1,963,518
|
|
|
49,167
|
|
|
1,951,444
|
|
|
2,198,812
|
|
Impairment of
assets
|
|
|
425,221
|
|
|
-
|
|
|
3,898,856
|
|
|
-
|
|
Impairment of
goodwill
|
|
|
-
|
|
|
-
|
|
|
3,197,391
|
|
|
-
|
|
General and
administrative expenses
|
|
|
9,865,330
|
|
|
7,794,808
|
|
|
29,176,130
|
|
|
24,730,168
|
|
Total corporate and
other costs
|
|
|
12,254,069
|
|
|
7,887,439
|
|
|
38,223,821
|
|
|
27,189,710
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
(loss)
|
|
|
9,662,745
|
|
|
(821,226)
|
|
|
16,411,402
|
|
|
(5,628,851)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense,
net
|
|
|
5,381,040
|
|
|
4,098,179
|
|
|
14,879,934
|
|
|
12,081,316
|
|
Loss on warrant
liability
|
|
|
6,733,552
|
|
|
-
|
|
|
1,072,709
|
|
|
-
|
|
Other (income)
expense
|
|
|
128,645
|
|
|
(53,206)
|
|
|
(712,049)
|
|
|
70,721
|
|
Income (loss) before
taxes
|
|
|
(2,580,492)
|
|
|
(4,866,199)
|
|
|
1,170,808
|
|
|
(17,780,888)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income tax expense
(benefit)
|
|
|
4,584,518
|
|
|
(342,259)
|
|
|
5,868,075
|
|
|
(2,068,530)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
|
(7,165,010)
|
|
|
(4,523,940)
|
|
|
(4,697,267)
|
|
|
(15,712,358)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Less: net income
(loss) attributable to
noncontrolling interests
|
|
|
1,623,303
|
|
|
1,018,451
|
|
|
4,819,169
|
|
|
(1,543,641)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss attributable
to Nutex Health Inc.
|
|
$
|
(8,788,313)
|
|
$
|
(5,542,391)
|
|
$
|
(9,516,436)
|
|
$
|
(14,168,717)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss per common
share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
$
|
(1.72)
|
|
$
|
(1.25)
|
|
$
|
(1.91)
|
|
$
|
(3.23)
|
|
Diluted
|
|
$
|
(1.72)
|
|
$
|
(1.25)
|
|
$
|
(1.91)
|
|
$
|
(3.23)
|
|
NUTEX HEALTH
INC.
CONDENSED
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
|
|
|
|
Nine Months Ended
September 30,
|
|
|
2024
|
|
2023
|
|
Cash flows from
operating activities:
|
|
|
|
|
|
|
|
Net income
(loss)
|
|
$
|
(4,697,267)
|
|
$
|
(15,712,358)
|
|
Adjustments to
reconcile net loss to net cash from operating
activities:
|
|
|
|
|
|
|
|
Depreciation and
amortization
|
|
|
13,691,484
|
|
|
12,908,848
|
|
Loss on warrant
liability
|
|
|
1,072,709
|
|
|
-
|
|
Impairment of
goodwill
|
|
|
3,197,391
|
|
|
-
|
|
Impairment of
assets
|
|
|
3,898,856
|
|
|
-
|
|
Derecognition of
goodwill
|
|
|
453,017
|
|
|
-
|
|
Stock-based
compensation expense
|
|
|
1,951,444
|
|
|
2,198,812
|
|
Deferred tax
benefit
|
|
|
(1,742,789)
|
|
|
(2,068,530)
|
|
Debt accretion
expense
|
|
|
804,760
|
|
|
1,251,867
|
|
Loss on lease
termination
|
|
|
-
|
|
|
58,210
|
|
Non-cash lease expense
(income)
|
|
|
(280,835)
|
|
|
89,338
|
|
Changes in operating
assets and liabilities, net of the effects of
acquisitions:
|
|
|
|
|
|
|
|
Accounts
receivable
|
|
|
(4,253,034)
|
|
|
4,444,706
|
|
Accounts receivable -
related party
|
|
|
549,879
|
|
|
(949,408)
|
|
Inventories
|
|
|
1,131,416
|
|
|
850,569
|
|
Prepaid expenses and
other current assets
|
|
|
(1,360,721)
|
|
|
(3,771,946)
|
|
Accounts
payable
|
|
|
(7,975,067)
|
|
|
(6,015,250)
|
|
Accounts payable -
related party
|
|
|
(39,314)
|
|
|
2,228,527
|
|
Accrued expenses and
other current liabilities
|
|
|
16,698,416
|
|
|
7,519,285
|
|
Net cash from
operating activities
|
|
|
23,100,345
|
|
|
3,032,670
|
|
|
|
|
|
|
|
|
Cash flows from
investing activities:
|
|
|
|
|
|
|
|
Acquisitions of
property and equipment
|
|
|
(1,908,651)
|
|
|
(10,322,487)
|
|
Cash related to sale of
business
|
|
|
(361,325)
|
|
|
-
|
|
Payments for
acquisitions of businesses, net of cash acquired
|
|
|
-
|
|
|
(743,837)
|
|
Cash related to
deconsolidation of Real Estate Entities
|
|
|
-
|
|
|
(1,039,157)
|
|
Net cash from
investing activities
|
|
|
(2,269,976)
|
|
|
(12,105,481)
|
|
|
|
|
|
|
|
|
Cash flows from
financing activities:
|
|
|
|
|
|
|
|
Proceeds from lines of
credit
|
|
|
1,132,168
|
|
|
2,340,911
|
|
Proceeds from notes
payable
|
|
|
7,014,999
|
|
|
16,952,905
|
|
Proceeds from
convertible notes
|
|
|
-
|
|
|
891,000
|
|
Repayments of lines of
credit
|
|
|
(1,119,327)
|
|
|
(1,592,714)
|
|
Repayments of notes
payable
|
|
|
(8,332,482)
|
|
|
(10,557,758)
|
|
Repayments of finance
leases
|
|
|
(1,923,687)
|
|
|
(2,704,082)
|
|
Proceeds from common
stock issuance, net issuance costs
|
|
|
9,202,500
|
|
|
-
|
|
Proceeds from exercise
of warrants
|
|
|
801,000
|
|
|
-
|
|
Members'
contributions
|
|
|
960,913
|
|
|
649,550
|
|
Members'
distributions
|
|
|
(3,659,228)
|
|
|
(4,335,532)
|
|
Net cash from
financing activities
|
|
|
4,076,856
|
|
|
1,644,280
|
|
Net change in cash and
cash equivalents
|
|
|
24,907,225
|
|
|
(7,428,531)
|
|
Cash and cash
equivalents - beginning of the period
|
|
|
22,002,056
|
|
|
34,255,264
|
|
Cash and cash
equivalents - end of the period
|
|
$
|
46,909,281
|
|
$
|
26,826,733
|
Non-GAAP Financial Measures (Unaudited)
EBITDA and Adjusted
EBITDA. EBITDA and Adjusted EBITDA are used
as a supplemental non-GAAP financial measure by management and
external users of our financial statements, such as industry
analysts, investors, lenders and rating agencies. We believe EBITDA
and Adjusted EBITDA are useful because it allows us to more
effectively evaluate our operating performance.
We define EBITDA as net income (loss) attributable to
Nutex Health Inc. plus interest expense, income taxes, depreciation
and amortization.
We define Adjusted EBITDA as net income (loss)
attributable to Nutex Health Inc. plus net interest expense,
income taxes, depreciation and amortization, further adjusted for
an allocation to noncontrolling interests, (gain)/loss on warrant
liability, stock-based compensation, certain defined items of
expense, and any acquisition-related costs and impairments. A
reconciliation of net income to EBITDA and Adjusted EBITDA is
included below. EBITDA and Adjusted EBITDA are not intended to
serve as an alternative to U.S. GAAP measures of performance and
may not be comparable to similarly-titled measures presented by
other companies.
|
|
Three Months Ended
September 30,
|
|
Nine Months Ended
September 30,
|
|
|
2024
|
|
2023
|
|
2024
|
|
2023
|
|
Reconciliation of net
loss attributable to Nutex Health
Inc. to Adjusted EBITDA:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss attributable
to Nutex Health Inc.
|
|
$
|
(8,788,313)
|
|
$
|
(5,542,391)
|
|
$
|
(9,516,436)
|
|
$
|
(14,168,717)
|
|
Depreciation and
amortization
|
|
|
4,972,478
|
|
|
4,745,941
|
|
|
13,691,484
|
|
|
12,908,848
|
|
Interest expense,
net
|
|
|
5,381,040
|
|
|
4,098,179
|
|
|
14,879,934
|
|
|
12,081,316
|
|
Income tax expense
(benefit)
|
|
|
4,584,518
|
|
|
(342,259)
|
|
|
5,868,075
|
|
|
(2,068,530)
|
|
Allocation to
noncontrolling interests
|
|
|
(1,808,422)
|
|
|
(1,772,908)
|
|
|
(4,980,424)
|
|
|
(3,500,873)
|
|
EBITDA attributable to
Nutex Health Inc.
|
|
|
4,341,301
|
|
|
1,186,562
|
|
|
19,942,633
|
|
|
5,252,044
|
|
Facilities closing
costs
|
|
|
-
|
|
|
-
|
|
|
-
|
|
|
217,266
|
|
Loss on warrant
liability
|
|
|
6,733,552
|
|
|
-
|
|
|
1,072,709
|
|
|
-
|
|
Impairment of
assets
|
|
|
425,221
|
|
|
|
|
|
3,898,856
|
|
|
|
|
Impairment of
goodwill
|
|
|
-
|
|
|
-
|
|
|
3,197,391
|
|
|
-
|
|
Acquisition
costs
|
|
|
-
|
|
|
43,464
|
|
|
-
|
|
|
43,464
|
|
Stock-based
compensation expense
|
|
|
1,963,518
|
|
|
49,167
|
|
|
1,951,444
|
|
|
2,198,812
|
|
Adjusted EBITDA
attributable to Nutex Health Inc.
|
|
$
|
13,463,592
|
|
$
|
1,279,193
|
|
$
|
30,063,033
|
|
$
|
7,711,586
|
About Nutex Health Inc.
Headquartered in Houston, Texas
and founded in 2011, Nutex Health Inc. (NASDAQ: NUTX) is a
healthcare management and operations company with two divisions: a
Hospital Division and a Population Health Management Division.
The Hospital Division owns, develops and operates innovative
health care models, including micro-hospitals, specialty hospitals,
and hospital outpatient departments (HOPDs). This division owns and
operates 22 facilities in ten states.
The Population Health Management division owns and operates
provider networks such as Independent Physician Associations
(IPAs). Through our Management Services Organization (MSO), we
provide management, administrative and other support services to
our affiliated hospitals and physician groups.
Forward-Looking Statements
Certain statements and information included in this press
release constitute "forward-looking statements" within the meaning
of the Private Securities Litigation Act of 1995. When used in this
press release, the words or phrases "will", "will likely result,"
"expected to," "will continue," "anticipated," "estimate,"
"projected," "intend," "goal," or similar expressions are intended
to identify "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Such statements
are subject to certain risks, known and unknown, and uncertainties,
many of which are beyond the control of the Company. Such
uncertainties and risks include, but are not limited to, our
ability to successfully execute our growth strategy, changes in
laws or regulations, including the interim final and final rules
implemented under the No Surprises Act , economic conditions,
dependence on management, dilution to stockholders, lack of
capital, the effects of rapid growth upon the Company and the
ability of management to effectively respond to the growth and
demand for products and services of the Company, newly developing
technologies, the Company's ability to compete, conflicts of
interest in related party transactions, regulatory matters,
protection of technology, lack of industry standards, the effects
of competition and the ability of the Company to obtain future
financing. An extensive list of factors that can affect future
results are discussed in the Annual Report on Form 10-K for the
year ended December 31, 2023 and in
the Quarterly Reports on Form 10-Q for the periods ending
March 31, 2024 and June 30, 2024 under the heading "Risk Factors" in
Part I, Item IA thereof, and other documents filed from time to
time with the Securities and Exchange Commission. Such factors
could materially adversely affect the Company's financial
performance and could cause the Company's actual results for future
periods to differ materially from any opinions or statements
expressed within this press release.
View original
content:https://www.prnewswire.com/news-releases/nutex-health-reports-third-quarter-and-year-to-date-september-30-2024-financial-results-302299409.html
SOURCE Nutex Health, Inc.